Opthea Limited

OPT | NASDAQ | 0 Followers
$3.41 +1.49% $0.05
Follow
Loading...

Profile

Opthea Limited is an Australian biotechnology company focused on the development and commercialization of innovative therapeutic solutions for eye diseases, particularly age-related macular degeneration (AMD) and diabetic macular edema. Founded in 2009, its main research focus is on developing drugs targeting the regulation of angiogenesis (the formation of new blood vessels) in the retina. Opthea is dedicated to advanced molecular therapies that offer new possibilities for treating eye diseases and improving visual function in patients. The company has several products in clinical trial phases and aims to bring them to the global market.

Feed

There are no posts to show right now.
Don't have an account? Join us

Log in to Bulios


Or use email and password
Already a member? Log in

Create Bulios profile

Continue with

Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools

Menu StockBot
Tracker
Upgrade